Novo Nordisk announces changes in Executive Management
Bagsværd, Denmark, 7 March 2023 – Novo Nordisk today announced the following changes in Executive Management.
Monique Carter, executive vice president (EVP), Global People & Organisation, has decided to leave Novo Nordisk to pursue an external opportunity, allowing her to be closer to her family in the UK. Monique Carter joined Novo Nordisk in 2018 as senior vice president (SVP) for People & Organisation, and in 2019 she was promoted to EVP, Global People & Organisation.
Tania Sabroe is promoted to EVP, Global People & Organisation, and will join Executive Management with immediate effect, succeeding Monique Carter. Tania Sabroe joined Novo Nordisk in August 2007 and comes from a position as SVP in Global People & Organisation. Previous to that she has held various positions of increasing importance and complexity in the field of people and organisation, sustainability and communication. Tania is a Danish national currently based in Switzerland where she worked in International Operations from 2013 to 2021.
Dave Moore is promoted to EVP, Corporate Development and will join Executive Management. Dave Moore joined Novo Nordisk in September 2022 as SVP for Corporate Development with the responsibility for strategy and business development. Before joining Novo Nordisk, Dave Moore held various leadership roles in the pharmaceutical industry in the US, working in international large pharma companies, biotech companies and private equity. From 2017 to 2019, Dave Moore was SVP for commercial operations in Novo Nordisk in the US. Dave is a US national and is based in the US.
With these changes, Executive Management will have the following members as of 7 March 2023:
- Lars Fruergaard Jørgensen, president and CEO
- Maziar Mike Doustdar, EVP, International Operations*
- Ludovic Helfgott, EVP, Rare disease*
- Karsten Munk Knudsen, EVP, chief financial officer
- Doug Langa, EVP, North America Operations*
- Martin Holst Lange, EVP, Development
- Dave Moore, EVP, Corporate Development*
- Tania Sabroe, EVP, People & Organisation*
- Marcus Schindler, EVP, chief scientific officer, Research & Early Development
- Camilla Sylvest, EVP, Commercial Strategy and Corporate Affairs
- Henrik Wulff, EVP, Product Supply, Quality & IT
* Not registered as an executive with the Danish Business Authority.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
|Ambre Brown Morley|
+45 3079 9289
|Natalia Salomao Abrahao (US)|
+1 848 304 1027
|Daniel Muusmann Bohsen|
+45 3075 2175
|Jacob Martin Wiborg Rode|
+45 3075 5956
|David Heiberg Landsted |
+45 3077 6915
|Mark Joseph Root (US) |
+1 848 213 3219
Company announcement No 17 / 2023
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- London: BioTrinity 2023